Product
Discover our solution
Use cases
Use Cases
Tour the product
Resources
Company
Join the team
Qohash Marketing
May 28, 2026
Table of contents
Minister Solomon to attend demonstration of Canadian surgical AI technology in Paris
Canadian technology being tested through France-based clinical partnership to support breast cancer surgery
Paris, May 28, 2026 — On the margins of the G7 Digital and Technology Ministerial Meeting under the French Presidency, the Honourable Evan Solomon, Canada’s Minister of Artificial Intelligence and Digital Innovation, attended a demonstration of Canadian surgical AI technology at the Académie nationale de chirurgie in Paris.
The demonstration highlighted a new partnership between Reveal Life Science, a Canadian medical technology company developing AI-supported surgical guidance tools, and IRCAD in Strasbourg, a world leader in surgical innovation and training.
The partnership builds on years of scientific and industrial development in Canada. Reveal’s technology has already been clinically evaluated in neurosurgery and is now being tested and validated for potential use in breast cancer surgery, with France as its first international clinical partner.
The Sentry platform, developed by Reveal Life Science, uses Raman spectroscopy and artificial intelligence to analyze tissue in real time during surgery. The goal: to allow the surgeon to immediately distinguish cancerous tissue from healthy tissue, directly in the operating room.
The problem is significant. Today, 433,000 women in France are diagnosed with breast cancer each year; of those, 250,000 will require oncological surgery. 15 to 40% of patients must undergo reoperation due to positive margins — a pathological result that does not arrive until 7 to 14+ days after surgery. Each reoperation represents an estimated additional cost of over US$20,000 per procedure based on published data from North American health systems, and above all, a physical and psychological ordeal for the patient.
The Sentry technology aims to reduce these reoperations by providing real-time molecular diagnostics. In neurosurgery, the technology has already demonstrated its ability to differentiate cancerous tissue from healthy tissue during procedures. The final pivotal study is planned for early 2027. With IRCAD, a large clinical validation study for breast cancer is now getting underway.
“We are not announcing an intention: we are announcing a technology that exists, that works, and that is entering an international deployment phase. Breast cancer is my priority: women represent 50% of the world’s population. Reducing reoperations, accelerating diagnosis, sparing millions of women a second surgery.” — Alexandre Triquet, Co-founder and CEO of Reveal Life Science
“We are not announcing an intention: we are announcing a technology that exists, that works, and that is entering an international deployment phase. Breast cancer is my priority: women represent 50% of the world’s population. Reducing reoperations, accelerating diagnosis, sparing millions of women a second surgery.”
— Alexandre Triquet, Co-founder and CEO of Reveal Life Science
This announcement comes at a strategic moment and demonstrates that Canada is not content to simply participate in discussions about AI: it is deploying concrete solutions, in a real clinical setting, with world-class partners.
The partnership rests on an entirely Canadian ecosystem: Reveal’s intellectual property, data security provided by Qohash, and clinical validations conducted at the Centre hospitalier de l’Université de Montréal (CHUM) and the McGill University Health Centre (MUHC). France, through IRCAD, the Centre Paul Strauss, and the University of Strasbourg, amplifies this technology toward Europe and the world.
The global surgical guidance market is estimated at US$3.9 billion in 2024 and is projected to reach US$7.5 billion by 2034, growing at an annual rate of 6.8%.
“Canada’s AI advantage is built on turning world-class research into trusted, real-world technology. Reveal Life Science is developing Canadian surgical AI with the potential to give surgeons better information in the operating room and support better outcomes for patients. With French clinical leadership, IRCAD’s global expertise, and secure Canadian data infrastructure from Qohash, this partnership shows how Canadian innovation can be tested, validated and brought to the world responsibly.” — The Honourable Evan Solomon, Canada’s Minister of Artificial Intelligence and Digital Innovation
IRCAD (Institut de recherche contre les cancers de l’appareil digestif), founded in 1994 by Professor Jacques Marescaux — pioneer of remote surgery and the first transatlantic operation (Operation Lindbergh, 2001) — trains more than 12,700 surgeons per year and operates a network of six institutes across four continents. The clinical study for breast cancer will be conducted at the Centre Paul Strauss under the direction of Professor Carole Mathelin, a European authority in breast surgery and former President of the Académie nationale de chirurgie.
“This partnership with Reveal Life Science represents exactly what IRCAD has always pursued: translating technological innovation into concrete benefit for the patient. A clinically validated Canadian artificial intelligence, deployed in our centres — this is international scientific cooperation at its finest.” — Professor Jacques Marescaux, founder of IRCAD, Strasbourg
“This partnership with Reveal Life Science represents exactly what IRCAD has always pursued: translating technological innovation into concrete benefit for the patient. A clinically validated Canadian artificial intelligence, deployed in our centres — this is international scientific cooperation at its finest.”
— Professor Jacques Marescaux, founder of IRCAD, Strasbourg
“Breast cancer remains the most common cancer in women. Giving the surgeon a molecular response quickly during surgery transforms patient care: fewer reoperations, less waiting, less suffering. This project places the patient at the heart of innovation.” — Professor Carole Mathelin, breast surgeon, University of Strasbourg — Centre Paul Strauss
“Breast cancer remains the most common cancer in women. Giving the surgeon a molecular response quickly during surgery transforms patient care: fewer reoperations, less waiting, less suffering. This project places the patient at the heart of innovation.”
— Professor Carole Mathelin, breast surgeon, University of Strasbourg — Centre Paul Strauss
The platform generates a new type of medical data at scale: a real-time intraoperative molecular dataset. This data is captured, structured, and secured by Reveal Atlas, the partnership’s sovereign data infrastructure, protected by Qohash, a Canadian cybersecurity champion.
Qohash’s technology makes it possible to see, understand, and protect sensitive data directly at the source, without moving it. Each country retains control of its own clinical data. This is a model of digital sovereignty applied to healthcare — intellectual property entirely developed and owned in Canada.
“In the age of artificial intelligence, control of sensitive data is a strategic advantage. Qohash ensures that the most critical medical data never leaves the control of those who hold it. This is the foundation of trusted AI: sovereign AI, powered by data protected at the source.” — Jean Le Bouthillier, founder and CEO of Qohash
“In the age of artificial intelligence, control of sensitive data is a strategic advantage. Qohash ensures that the most critical medical data never leaves the control of those who hold it. This is the foundation of trusted AI: sovereign AI, powered by data protected at the source.”
— Jean Le Bouthillier, founder and CEO of Qohash
Qohash and Reveal:
Alexandra Bernier
Vice-President, Strategic Affairs and Government Relations — Qohash
[email protected] | 418-809-3072
Canadian Embassy:
Patricia Bénitah — PB Communication
Press Attaché, Académie nationale de chirurgie
Discover Qohash's zero-copy data security. Schedule your demo today.